aibioPfizer
Top story · Aug 4, 2026 · Company press release
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance ■ Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products (1) ■ Advancing...
- Ticker
- PFE
- Listing
- NYSE, United States
- Next date
- October 23 to 27, 2026
- Chief executive
- Albert Bourla
Desk view · Opinion · Updated Oct 22, 2026
Pfizer has cut its way to stability, but growth after Eliquis still rests on phase 3 bets
Pfizer has stabilized its business with growing non-COVID sales, a strong Padcev franchise and more than $10 billion in cost cuts. Growth after the Eliquis cliff depends on obesity and oncology programs that have not yet produced late-stage data, and the sigvotatug vedotin miss weakened the Seagen story.
Read the full desk viewaibio.space Investor Rank · Opinion
5/10 Neutral view
Padcev and cost cuts have stabilized the business, but heavy debt, the Eliquis cliff and a Seagen ADC miss leave growth resting on unproven phase 3 bets.
- Technology
- 1/2
- Odds
- 1/2
- Balance sheet
- 1/2
- Risk
- 1/2
- Momentum
- 1/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Two bought platforms. Padcev is a proven ADC winner, while the next Seagen ADC failed and obesity is still in phase 3.
- Odds
- Good near term, unproven long term. Talzenna's FDA decision is due in Q4 2026, but berobenatide and the PD-1 x VEGF bispecific lack late-stage data.
- Balance sheet
- Profitable but indebted. About $11.7 billion in cash and short-term investments against $63.2 billion of debt at June 28, 2026.
- Main risk
- Patent cliff timing. Eliquis loses protection before obesity and new oncology drugs can scale, with growth seen returning from 2028.
- Watch next
- ESMO data, October 23 to 27. Then third-quarter results on November 3 and the Talzenna FDA decision in Q4.
Top news on Pfizer
- Distress
Pfizer expands cost realignment program, adds $1.2 billion in expected savings
Pfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program.
Questions investors ask
What is aibio.space's Investor Rank for Pfizer?
5 out of 10, our neutral view. Padcev and cost cuts have stabilized the business, but heavy debt, the Eliquis cliff and a Seagen ADC miss leave growth resting on unproven phase 3 bets. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
What is Pfizer's 2026 revenue guidance?
On August 4, 2026, Pfizer raised the midpoint of its 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion. It kept adjusted earnings guidance at $2.80 to $3.00 per share. Source
What is berobenatide?
Berobenatide is a GLP-1 receptor agonist peptide that Pfizer gained through its Metsera acquisition and is developing for monthly dosing in obesity. Pfizer plans 10 phase 3 studies in 2026. Source
Why did Pfizer take a $3.8 billion impairment in 2026?
BNN Bloomberg reported that the second-quarter GAAP loss included a $3.8 billion impairment on sigvotatug vedotin. The lung cancer ADC failed to improve overall survival against docetaxel in the phase 3 SigVie-002 trial. Source
Is Padcev approved for muscle-invasive bladder cancer?
Yes. In July 2026 the FDA approved Padcev with Keytruda before and after surgery for adults with muscle-invasive bladder cancer regardless of cisplatin eligibility. Source
When does Pfizer report third-quarter 2026 earnings?
Pfizer will issue its third-quarter 2026 report on the morning of November 3, 2026, with an analyst call at 10:00 a.m. EST. Source
What is the latest Pfizer (PFE) stock news?
Our latest story on Pfizer, dated Apr 29, 2025: "Pfizer expands cost realignment program, adds $1.2 billion in expected savings". Pfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program. Source
How much cash does Pfizer have?
From our story of Apr 29, 2025: It paid $2.4 billion in cash dividends, or $0.43 per share. Source
Is Pfizer in financial distress?
Our latest distress story, dated Apr 29, 2025: "Pfizer expands cost realignment program, adds $1.2 billion in expected savings". Pfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program. Source
What is Pfizer's market cap?
We do not publish live share prices. In its annual report, Pfizer, Inc. put the market value of shares held by non-affiliates (public float) at $138.00 billion as of Jun 29, 2025. Source
Is Pfizer a smaller reporting company?
SEC records list Pfizer, Inc.'s filer category as: Large accelerated filer. Source
Where is Pfizer headquartered?
SEC records list its business address as 66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192. Source
When does Pfizer's fiscal year end?
Pfizer, Inc.'s fiscal year ends on December 31, per SEC records. Source
What did Pfizer last file with the SEC?
Its most recent filing in our record is a 10-Q filed 2026-08-04. All of its filings are on SEC EDGAR. Source
What was Pfizer called before?
SEC records list these former names: PFIZER INC. Source
Legal and investor matters
Pfizer's 10-Q filed 2026-08-04 (Note 12A, Legal Proceedings) lists categories of legal contingencies including patent litigation, product litigation, commercial and other matters, and government investigations. Source
- Litigation
Pfizer reaches agreement in principle in Chantix class litigation
Pfizer's 10-Q says putative class actions filed from August 2021 after the voluntary Chantix recall over a nitrosamine were consolidated in a multidistrict litigation in the Southern District of New York. Plaintiffs say they suffered economic harm and seek to represent nationwide and state classes. In March 2026 the parties reached an agreement in principle to resolve the litigation on terms Pfizer describes as not material. It needs final court approval.
- Litigation
Pfizer reaches agreement in principle in Depo-Provera MDL
Pfizer reports lawsuits in federal and state courts alleging that women who used injectable Depo-Provera for contraception developed meningioma. The federal cases were transferred in February 2025 to a multidistrict litigation in the Northern District of Florida. In June 2026 Pfizer reached an agreement in principle with plaintiff leadership that it expects to resolve a substantial majority of the pending MDL cases, on terms it says are not material to its liquidity or financial condition.
- Litigation
State attorneys general antitrust suits over Greenstone generics continue
Pfizer's 10-Q describes complaints filed in 2019 and 2020 by attorneys general of more than 50 states and territories in the District of Connecticut against pharmaceutical companies including Pfizer and its former generics subsidiary Greenstone. The complaints allege anticompetitive conduct in violation of antitrust and consumer protection laws. The state cases were transferred back to Connecticut in April 2024, and related private suits sit in a Pennsylvania multidistrict litigation.
- Litigation
Pfizer settles Vyndaqel and Vyndamax patent suits; generic Vyndamax launch permitted from June 2031
Pfizer reports that in March 2026 it settled the Vyndaqel patent case, and in April 2026 it settled three Vyndamax cases, with generic filers in the District of Delaware. Under the settlements, the generic companies may launch generic Vyndamax capsules on 2031-06-01, subject to the outcome of other litigation. An action against Apotex relating to Vyndamax is ongoing.
- Regulatory
Pfizer 10-Q lists DOJ and SDNY requests on its India operations; Pfizer has produced records
In its government investigations discussion, Pfizer's 10-Q says that in March 2020 it received an informal request from the U.S. Department of Justice's Consumer Protection Branch for documents on its manufacturing operations in India. In April 2020 it received a similar request from the U.S. Attorney's Office for the Southern District of New York regarding a civil investigation concerning its facilities in India. Pfizer says it has produced records pursuant to these requests.
- Governance
Shareholders reject independent chair proposal at 2026 annual meeting
Pfizer reported the results of its 2026 annual meeting in a Form 8-K filed 2026-04-27. A shareholder proposal to adopt an independent chair policy was not approved. It received 1,015,206,372 votes for and 2,509,042,021 votes against, with 32,354,566 abstentions and 941,392,137 broker non-votes. The same filing reports the results of the other items voted on at the 2026 annual meeting.
- Financing
Pfizer completes multi-tranche U.S. dollar notes offering
On 2025-11-21 Pfizer completed a public offering of seven series of notes. They included $500,000,000 of floating rate notes due 2027, $1,250,000,000 of 4.500% notes due 2032, $1,250,000,000 of 4.875% notes due 2035 and $500,000,000 of 5.700% notes due 2065. Pfizer's 8-K filed that day reports the offering under Item 8.01.
- Litigation
Pfizer completes Metsera acquisition; Pfizer had sued Metsera and Novo Nordisk in Delaware
Pfizer completed its acquisition of Metsera on 2025-11-13 at $65.60 per share in cash plus a contingent value right of up to $20.65 per share, an enterprise value of about $7.0 billion. In October and November 2025 Pfizer filed lawsuits against Metsera, Novo Nordisk and related parties in the Delaware Court of Chancery and the federal court in Delaware over a competing proposal Novo made on 2025-10-25. Pfizer's 10-Q describes claims including breach of contract and tortious interference.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| Berobenatide (PF'3944, formerly MET-097i) | Obesity and weight-related conditions (monthly GLP-1) | Phase 3 (10 studies planned in 2026) Source |
| Talzenna + Xtandi | HRR gene-altered metastatic castration-sensitive prostate cancer | sNDA under FDA priority review, decision Q4 2026 Source |
| PF-08634404 (PD-1 x VEGF bispecific) | First-line NSCLC, colorectal and endometrial cancer | Registrational studies ongoing Source |
| Sigvotatug vedotin + pembrolizumab | First-line NSCLC with PD-L1 of at least 50% | Phase 3 (monotherapy missed in second line) Source |
| Padcev + Keytruda | Muscle-invasive bladder cancer | FDA approved July 2026 Source |
Opinion · Devil's advocate
Fact-check-o-meter
Pfizer's filings back its numbers, but the obesity and lung-cancer messages are more upbeat than the data behind them
Pfizer's second-quarter release and 10-Q agree on the financials, and the release leads with the reported loss and the $4.3 billion of impairments. The softer spots are in the pipeline messaging: a lung-cancer ADC that missed its survival goal was described in terms of a subgroup, and the obesity headline rests on an exploratory weekly-dose figure.
Press release vs filing · weight high
Sigvotatug: subgroup optimism vs a missed primary endpoint and a $3.8 billion write-down
The company said: "Although the study did not meet its overall survival endpoint, in second-line patients the data suggest a clinically meaningful survival benefit" source
The record says: The 10-Q states the study "did not meet its primary endpoint of a statistically significant improvement in overall survival compared to docetaxel" and records "$ 3.8 billion in impairments of IPR&D assets, associated with a Phase 3 study for sigvotatug vedotin for the second line treatment of metastatic non-squamous NSCLC, reflecting unfavorable clinical trial results." source
Our view: The June release is open that the primary endpoint was missed, but the second-line trend language sits beside no hazard ratio or survival numbers. The accounting treatment shows how Pfizer itself valued the result: as an impairment, not a delay.
Science · weight medium
Berobenatide headline weight loss is a non-placebo-adjusted, exploratory figure
The company said: "non-placebo-adjusted weight loss of 15.9%" source
The record says: The same release says the figure came from participants who escalated from placebo to 2.4 mg weekly berobenatide, with "no plateau observed at 32 weeks on berobenatide," and that "Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026." The release does not give enrollment numbers or discontinuation rates for the phase 2b trials, describing GI events and discontinuations only as "low." source
Our view: The headline is a weekly-dose number from an extension part, while the title promotes monthly dosing. Without placebo-adjusted data, sample sizes or numeric discontinuation rates, cross-trial comparisons with other obesity drugs are not possible from this release.
Press release vs filing · weight low
Reported loss and adjusted profit are both prominent
The company said: "Second-Quarter 2026 Reported Loss Per Share of $(0.04), and Adjusted Diluted EPS of $0.77" source
The record says: The release adds "Reported Loss Per Share Reflects $4.3 Billion in Non-Cash Intangible Asset Impairments." The 10-Q carries the same impairments, including $525 million for Oxbryta after "there was no viable pathway to return Oxbryta to the market in the U.S." source
Our view: Pfizer puts GAAP and adjusted figures in the same headline and says what drove the gap, so there is no mismatch here. The Oxbryta and sigvotatug charges together total $4.3 billion, which is what the 'adjusted' number leaves out of the reported loss.
Legal and disclosure record · weight medium
Product, patent and government matters disclosed; no securities class action in the legal note
The record says: Note 12A lists Zantac cases in an MDL in the U.S. District Court for the Southern District of Florida, Chantix putative class actions in an MDL in the Southern District of New York ("In March 2026, the parties reached an agreement in principle to resolve the litigation on terms not material to Pfizer"), Depo-Provera cases ("In June 2026, we reached an agreement-in-principle with plaintiff leadership in the Depo-Provera MDL") and DOJ requests relating to its India manufacturing operations (March 2020). source
Our view: These are documented matters in the filing, not findings of wrongdoing. The legal note describes no securities class action against Pfizer in the sections we read.
Stock chart
SEC filings and registration
- SEC name
- Pfizer Inc
- CIK
- 78003
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- PFE (NYSE)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192
- Phone
- 2127332323
- Shares outstanding
- 5,699,673,589 as of 2026-07-29 (10-Q filed 2026-08-04)
- Former names
- PFIZER INC
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction